U-75875
U-75875 is a HIV-1 protease inhibitor. U-75875 can block Gag-Pol protein processing and viral maturation and replication. U-75875 can be used for the research of infection.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 112190-24-6
- 分子式: C45H61N7O7
- 分子量:812.01
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CV-1 | IC50 |
0.2 μM
Compound: U-75875
|
Antiviral efficacy measured by a hybrid HIV-l/vaccinia virus infected monkey cell line (HIV- l/vVK-1 infected CV- 1) which produces HIV-1 gag-pol derived polyproteins
Antiviral efficacy measured by a hybrid HIV-l/vaccinia virus infected monkey cell line (HIV- l/vVK-1 infected CV- 1) which produces HIV-1 gag-pol derived polyproteins
|
10.1016/S0960-894X(00)80673-3 |
体外実験
U-75875 shows an IC50 of 100 μM to SIV-infected PBMC cultures[1].
U-75875 (0.1 μM, 2 h) reduces HIV-1 p24 Ag levels in human fetal brain cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rhesus monkeys infected with SIV Delta B670[1]
-
Dosage:7 and 20 mg/kg
-
Administration:Intravenously injection, daily for 26 days
-
Result:Decreased the level of proviral DNA in peripheral blood mononuclear cells.
Decreased titer of infectious virus.
化学情報
-
CAS 番号 112190-24-6
-
分子量 812.01
-
分子式 C45H61N7O7
-
SMILES
O=C(NCC1=CC=CC=N1)[C@H]([C@@H](C)CC)NC([C@H](C(C)C)[C@@H](O)[C@H](O)[C@H](CC2CCCCC2)NC([C@H](CC3=CN=CN3)NC(COC4=CC=CC5=C4C=CC=C5)=O)=O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
[1]. Martin LN, et al. Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys. Antimicrob Agents Chemother. 1994 Jun;38(6):1277-83. [Content Brief]
[2]. Peterson PK, et al. Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures. Antimicrob Agents Chemother. 1994 Oct;38(10):2465-8. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
U-75875 関連分類
HY-105448 関連分類
Powered by Bioz